Dharnidharka VR, Ruzinova MB, Chen C‐C, et al. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders. Cancer Med. 2019;8:1013‐1023. 10.1002/cam4.1985

**Funding information** Funded through grant MC‐II‐2014‐394 from Children\'s Discovery Institute, St. Louis MO USA.

1. BACKGROUND {#cam41985-sec-0001}
=============

Posttransplant lymphoproliferative disorders (PTLDs), an abnormal proliferation of lymphoid cells under posttransplant immunosuppression, are a major malignant complication of organ and tissue transplant.[1](#cam41985-bib-0001){ref-type="ref"}, [2](#cam41985-bib-0002){ref-type="ref"}, [3](#cam41985-bib-0003){ref-type="ref"}, [4](#cam41985-bib-0004){ref-type="ref"} PTLDs have a high morbidity and 5‐year mortality that exceeds 50%.[3](#cam41985-bib-0003){ref-type="ref"} About 50%‐80% of PTLD cases are strongly related to the oncogenic Epstein‐Barr virus (EBV).[5](#cam41985-bib-0005){ref-type="ref"} Cytomegalovirus seromismatch has been associated in some studies[6](#cam41985-bib-0006){ref-type="ref"}, [7](#cam41985-bib-0007){ref-type="ref"} but not consistently. It is not known whether other viruses are also associated with PTLD. While recent mortality rates have decreased with general medical advances and newer therapies,[8](#cam41985-bib-0008){ref-type="ref"}, [9](#cam41985-bib-0009){ref-type="ref"} mortality remains high[10](#cam41985-bib-0010){ref-type="ref"} and graft failure is a significant complication of interventions.[11](#cam41985-bib-0011){ref-type="ref"} Though many prognostic indices have been used to predict survival after PTLD, mortality after PTLD is not fully explained by these indices.[12](#cam41985-bib-0012){ref-type="ref"}, [13](#cam41985-bib-0013){ref-type="ref"}, [14](#cam41985-bib-0014){ref-type="ref"} These indices vary considerably in their component prognostic factors; they do not consistently include the same clinical, viral, epidemiologic or tumor characteristics. Therefore, host responses to EBV and the degree of overall immunosuppression have been studied as possible contributors to prognosis and outcome, but still do not fully explain the outcomes.[15](#cam41985-bib-0015){ref-type="ref"}, [16](#cam41985-bib-0016){ref-type="ref"}, [17](#cam41985-bib-0017){ref-type="ref"}

Our aim was to determine whether there were DNA viruses associated with EBV‐negative PTLD or PTLD outcomes using metagenomic shotgun sequencing (MSS) of archived formalin‐fixed paraffin‐embedded (FFPE) tissue samples from PTLD patients. MSS is an approach that assesses genomic material from host and microbes within a sample, allowing for the culture‐independent detection of microbes without a priori knowledge of which viral groups are present with a sample. Like genome‐wide association tools, MSS is a powerful tool for studying viruses in clinical samples because it allows evaluation of a comprehensive set of viruses simultaneously. In addition, MSS can provide genomic data that can be used to assess features or variants that may associate with virulence or pathogenicity. Our approach included the use of ViroCap^™^, a targeted sequence capture method that we developed recently to enhance detection of viral sequences by MSS.[18](#cam41985-bib-0018){ref-type="ref"} This improved methodology allows us to thoroughly characterize the viruses associated with PTLD, and eventually study how EBV genome variants contribute to more severe presentations or worse outcomes. We can also study which viruses, if any, are associated with EBV‐negative PTLD. We undertook this genomic analysis because these newer technologies could lead to new information and insights not found with other methods.

2. METHODS {#cam41985-sec-0002}
==========

This study was approved the Human Subjects Research Protection Office at Washington University School of Medicine.

2.1. Tissue sample identification {#cam41985-sec-0003}
---------------------------------

We first identified through a search of our electronic medical records that all tissue blocks from PTLD cases available in the tissue archives of the Washington University School of Medicine Pathology Department. Tissue specimens of sufficient quantity (as evaluated by hematopathologist MBR) were selected for nucleic acid extraction. We also identified 8 EBV‐negative control tissues (abdominal lymph nodes from cases of diverticulitis, prolapse, appendicitis or gunshot wound) and four positive EBV‐positive control tissues that were either Hodgkin lymphoma or diffuse large B cell lymphoma (DLBCL) from immunocompetent patients in a nontransplant setting. Pathological and clinical covariates extracted for the PTLD specimens are described in [Supplementary Methods](#cam41985-sup-0001){ref-type="supplementary-material"}.

2.2. DNA extraction and MSS {#cam41985-sec-0004}
---------------------------

DNA extraction methods are described in [Supplementary Methods](#cam41985-sup-0001){ref-type="supplementary-material"}. We generated dual‐indexed sequencing libraries from the DNA using the KAPA Low Throughput Library Construction Kit (KAPA Biosystems, Wilmington, Massachusetts). We pooled libraries and mixed them with the ViroCap^™^ targeted sequence capture probes (synthesized by Nimblegen^®^), which target and enrich genomes from a comprehensive set of vertebrate viruses to enhance sensitivity. Targeted sequence capture was carried out according to the manufacturer\'s instructions. We sequenced the enriched viral nucleic acids using the Illumina HiSeq 2000/2500 platform. We analyzed sequences using a pipeline adapted from the method previously described by us[19](#cam41985-bib-0019){ref-type="ref"} except that Burroughs Wheeler Alignment tool BWA MEM was used for the nucleotide sequence alignments.[20](#cam41985-bib-0020){ref-type="ref"} To avoid false positives resulting from index swapping during capture,[21](#cam41985-bib-0021){ref-type="ref"}, [22](#cam41985-bib-0022){ref-type="ref"}, [23](#cam41985-bib-0023){ref-type="ref"} in which the library‐specific indexes are transferred between libraries at a low frequency, we subtracted 0.1% of the total viral reads for each virus within a pool from each sample. This threshold was based on published studies[21](#cam41985-bib-0021){ref-type="ref"}, [22](#cam41985-bib-0022){ref-type="ref"}, [23](#cam41985-bib-0023){ref-type="ref"} and our experience with capture of dual‐indexed sequencing libraries.[18](#cam41985-bib-0018){ref-type="ref"} Samples with viral signal above or below that threshold were considered positive or negative, respectively, as a categorical variable. Sequences were manually reviewed to verify classification of herpesvirus and polyomavirus sequences.

2.3. EBV variant analysis {#cam41985-sec-0005}
-------------------------

For samples that were positive for EBV sequences, sequences were aligned to canonical EBV‐1 and EBV‐2 reference genomes (NCBI Reference Sequence: NC_007605.1 and NC_009334.1). The depth and breadth of coverage were calculated using RefCov (<http://gmt.genome.wustl.edu/packages/refcov/>), and alignments were reviewed to determine EBV type. Samples in which \>70% of the EBV‐1 genome represented in the sequencing data were included in subsequent comparative analysis. Variants compared to the reference EBV‐1 genome were identified using Varscan, a platform‐independent software tool developed at the McDonnell Genome Institute at Washington University to detect variants in genomic data.[24](#cam41985-bib-0024){ref-type="ref"} For variant analysis, nucleotide positions with \<10× read depth were classified as unevaluable and excluded. Variants and coverage were manually reviewed using Tablet, a high‐performance graphical viewer for metagenomic sequence assemblies and alignments.[25](#cam41985-bib-0025){ref-type="ref"}

2.4. Data submission {#cam41985-sec-0006}
--------------------

Submission of microbial sequencing data to the public Sequence Read Archive is in progress at the time of submission, and BioProject and SRS identifiers will be provided prior to publication.

### 2.4.1. Polymerase chain reaction {#cam41985-sec-0007}

Tissue specimens were tested by quantitative PCR assays for EBV and the predominant anellovirus species in humans, torque teno virus (TTV), alpha subtype. Details of the PCR assays are described in the [Supplementary Methods](#cam41985-sup-0001){ref-type="supplementary-material"}.

### 2.4.2. Statistical analyses {#cam41985-sec-0008}

Details of the statistical analyses are in the [Supplementary Methods](#cam41985-sup-0001){ref-type="supplementary-material"}.

3. RESULTS {#cam41985-sec-0009}
==========

3.1. Subjects and samples {#cam41985-sec-0010}
-------------------------

We identified 163 records in the Department of Pathology tissue archives, of which 69 specimens from 60 subjects from the period 1991‐2015 were adequate for analysis according to the described criteria. The male: female ratio was 36:24. The median age of the subjects was 15.1 years (range 0.1 to 67.9 years; mean 22.7, \<21 years at time of transplant = 35/60). Subjects with polymorphic PTLD were younger at transplant (median age 13.0 years) than other groups, while the subjects with T cell PTLD were older at transplant (median age 40.7 years) than other groups (Table [1](#cam41985-tbl-0001){ref-type="table"}).

###### 

Study subject (n = 60) and sample (n = 69) characteristics

                                                                        Polymorphic     DLBCL           Burkitt/Plasma Cell   T cell          Classic Hodgkin   Total
  --------------------------------------------------------------------- --------------- --------------- --------------------- --------------- ----------------- -------
  Patients                                                              16              30              3                     5               6                 60
  Age at transplant (years ± SD)                                        12.98 ± 17.16   27.78 ± 22.90   15.23 ± 25.78         40.66 ± 23.43   28.57 ± 17.35     
  Age at transplant under 21 years                                      14 (87.5)       16 (53.33)      2 (66.67)             1 (20)          2 (33.33)         35
  Male                                                                  11 (68.75)      16 (53.33)      2 (66.67)             3 (60)          4 (66.67)         36
  Subject death[a](#cam41985-note-0003){ref-type="fn"}                  6 (37.5)        14 (46.67)      1 (33.33)             4 (80)          1 (16.67)         26
  Death‐censored graft failure[a](#cam41985-note-0003){ref-type="fn"}   2 (12.5)        2 (6.67)        0 (0)                 0 (0)           1 (16.67)         5
  Organ transplant type                                                 16              30              3                     5               6                 60
  Kidney                                                                3 (18.75)       5 (16.67)       0 (0)                 3 (60)          4 (66.67)         15
  Liver                                                                 0 (0)           5 (16.67)       0 (0)                 0 (0)           0 (0)             5
  Heart                                                                 2 (12.5)        6 (20)          1 (33.33)             0 (0)           0 (0)             9
  Lung                                                                  9 (56.25)       11 (36.67)      2 (66.67)             2 (40)          1 (16.67)         25
  Bone marrow                                                           1 (6.25)        0 (0)           0 (0)                 0 (0)           1 (16.67)         2
  Multiple                                                              1 (6.25)        3 (10)          0 (0)                 0 (0)           0 (0)             4
  Median months from transplant to PTLD (Q1, Q3)                        37 (6, 69)      28.5 (7, 127)   97 (85, 145)          132 (57, 164)   116 (102, 199)    
  Sample location                                                       18              34              5                     6               6                 69
  Lymph node                                                            7 (38.89)       4 (11.76)       1 (20)                1 (16.67)       6 (100)           19
  GI tract                                                              1 (5.56)        14 (41.18)      5 (100)               1 (16.67)       0 (0)             21
  Liver                                                                 1 (5.56)        5 (14.71)       0 (0)                 0 (0)           0 (0)             6
  CNS                                                                   0 (0)           2 (5.88)        0 (0)                 1 (16.67)       0 (0)             3
  Disseminated                                                          1 (5.56)        3 (8.82)        1 (20)                3 (50)          1 (16.67)         9
  Bone Marrow                                                           1 (5.56)        0 (0)           0 (0)                 2 (33.33)       0 (0)             3
  Lung                                                                  2 (11.11)       6 (17.65)       0 (0)                 0 (0)           0 (0)             8
  Other                                                                 7 (38.89)       6 (17.65)       0 (0)                 3 (50)          0 (14.29)         16

Numbers in parentheses indicate percentages. DLBCL, diffuse large B cell lymphoma.

Subject death and death‐censored graft failure were assessed within 5 years of the diagnosis of PTLD.
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The transplanted organ was distributed across all the major types, lung being the most common (Table [1](#cam41985-tbl-0001){ref-type="table"}). PTLD was located in diverse locations, lymph node and GI tract being the most common. Applying the World Health Organization (WHO) classification of PTLD,[26](#cam41985-bib-0026){ref-type="ref"}, [27](#cam41985-bib-0027){ref-type="ref"} our 69 tissue cases were mostly monomorphic B cell type in 39 (of which 34 were DLBCL and five were other types). For the 8 subjects who had more than 1 PTLD occurrence (one subject had two recurrences), the PTLD WHO type was the same in each occurrence, except in one subject, who had a Hodgkin type PTLD initially and a DLBCL type in the recurrence 3 years later.

Death‐censored graft failure occurred in 8/60 (six in patients who later died) at a median time of 3.2 years after PTLD diagnosis (IQR 0.6‐7.2 years). Of the eight graft failures, five grafts failed within 5 years of the PTLD diagnosis. Thirty‐two patients had died at the time the samples were analyzed, at a median time of 3.5 years after PTLD diagnosis (IQR 0.7‐8.1 years, range 0--18.8 years). Of the 32 deaths, 26 died within 5 years of the PTLD diagnosis.

3.2. Detection of viral nucleotide sequences by MSS {#cam41985-sec-0011}
---------------------------------------------------

Nucleotide sequences from at least one virus were detected by MSS in 86% (59/69) of the sequenced PTLD samples. Figure [1](#cam41985-fig-0001){ref-type="fig"} depicts the viral sequences detected. EBV was detected in 61% (42/69) of the PTLD samples, and it was also detected in all of the 4 EBV positive control samples but not in any of the eight negative controls. Of the single‐stranded DNA viruses, anelloviruses were detected in 52% of the PTLD samples. Positivity by MSS for a viral genus was handled as a categorical yes/no variable in further analyses. When correlating with WHO classification, all six Hodgkin lymphoma cases were EBV sequencing positive and 5/6 were roseolovirus positive while all six T cell PTLDs were EBV sequencing negative (see Figure [1](#cam41985-fig-0001){ref-type="fig"} for breakdown according to WHO PTLD type and see Figure [S1](#cam41985-sup-0001){ref-type="supplementary-material"}). Anellovirus positivity by MSS did not associate with PTLD WHO type (Figure [S1](#cam41985-sup-0001){ref-type="supplementary-material"}).

![DNA viruses detected in stored PTLD tissues, stratified by WHO type. Each row represents a different sequenced sample. Viruses are noted in columns. A dark bar indicates the virus was detected in that sample, and gray background indicates the virus was not detected](CAM4-8-1013-g001){#cam41985-fig-0001}

3.3. EBV genome variants {#cam41985-sec-0012}
------------------------

We had \>70% of the EBV genome length represented in the sequence data from samples from 37 unique PTLD patients, 33 EBV‐1 and 4 EBV‐2. The 33 EBV‐1 samples were used for subsequent comparative analysis. We chose to focus on nine specific EBV genes that are most associated with oncogenesis or with viral latency profiles.[2](#cam41985-bib-0002){ref-type="ref"} We determined the nucleotide variants in each of these nine genes and classified variants as synonymous (no change in the predicted amino acid coding) vs nonsynonymous (predicted change in the amino acid coding, and therefore more likely to be pathogenic). As shown in Table [2](#cam41985-tbl-0002){ref-type="table"}, the genes *EBNA3C, EBNA‐LP,* and *LMP1* had a greater ratio of nonsynonymous changes to synonymous changes, suggesting a greater chance of pathogenic variants within these genes. Logistic regression analyses showed that the genes with the highest percent nonsynonymous changes were *EBNA‐LP* (significantly higher than all other genes), and *EBNA1* and *EBNA3C* (significantly lower than *EBNA‐LP* but significantly higher than all other genes; Figure [2](#cam41985-fig-0002){ref-type="fig"}).

###### 

Changes found in nine Epstein‐Barr virus genes in 33 PTLD tissues, compared to the reference EBV‐1 genome. Bolded numbers represent genes where the percentage of nonsynonymous changes (change in coded amino acid) was significantly higher than in other genes evaluated (see also Figure [2](#cam41985-fig-0002){ref-type="fig"})

  Gene      Total nucleotide positions in gene[a](#cam41985-note-0004){ref-type="fn"}   Variant nucleotide positions[c](#cam41985-note-0007){ref-type="fn"} (percentage of total positions)[c](#cam41985-note-0006){ref-type="fn"}   Total variant positions compared in 33 tissues[d](#cam41985-note-0007){ref-type="fn"} ^,^ [e](#cam41985-note-0008){ref-type="fn"}   Evaluable nucleotide positions[e](#cam41985-note-0009){ref-type="fn"}   Positions with no change (% of evaluable)   No. of synonymous changes (% of evaluable)   No. of nonsynonymous changes (% of evaluable)
  --------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------- -------------------------------------------- -----------------------------------------------
  EBNA1     1926                                                                        23 (1.19)                                                                                                                                    759                                                                                                                                 553                                                                     379 (68.5)                                  89 (16.8)                                    85 (**15.4**)
  EBNA2     1464                                                                        10 (0.68)                                                                                                                                    330                                                                                                                                 278                                                                     241 (86.7)                                  20 (7.2)                                     17 (6.1)
  EBNA3A    2835                                                                        31 (1.09)                                                                                                                                    1023                                                                                                                                877                                                                     764 (87.1)                                  47 (5.4)                                     66 (7.5)
  EBNA3B    2817                                                                        35 (1.24)                                                                                                                                    1155                                                                                                                                967                                                                     851 (88.0)                                  57 (5.9)                                     59 (6.1)
  EBNA3C    2979                                                                        46 (1.54)                                                                                                                                    1518                                                                                                                                1305                                                                    959 (73.4)                                  117 (9.0)                                    229 (**17.5**)
  EBNA‐LP   1521                                                                        3 (0.2)                                                                                                                                      99                                                                                                                                  89                                                                      42 (47.1)                                   5 (5.6)                                      42 (**47.2**)
  LMP1      1161                                                                        220 (17.23)                                                                                                                                  6600                                                                                                                                5629                                                                    5099 (90.6)                                 97 (1.7)                                     433 (7.7)
  LMP2A     1493                                                                        25 (1.67)                                                                                                                                    825                                                                                                                                 727                                                                     614 (98.0)                                  57 (7.8)                                     56 (7.7)
  LMP2B     1137                                                                        21 (1.85)                                                                                                                                    693                                                                                                                                 617                                                                     523 (84.8)                                  54 (8.8)                                     40 (6.5)

Total nucleotide positions in the coding sequence of each gene.

A position is considered "variant" if the nucleotide defined by MSS in one or more of the 33 samples analyzed differs from the reference nucleotide at that position.

Percentage of coding sequence nucleotide positions for which a variant from the reference sequence is shown to be present in one or more samples.

Total subjects' nucleotide positions of change for each gene. For example, EBNA1, 759 equals 23 nucleotide positions of change × 33 specimens.

Total positions compared = \# of synonymous changes + \# of nonsynonymous changes + \# no change + \# positions without enough coverage to evaluate.

A nucleotide position was considered evaluable in a specific sample if it was represented in 10 or more sequencing reads.
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![Plots of adjusted percent nonsynonymous sequence changes (nonsynonymous\*100/nonsynonymous + synonymous + no change) in **EBV** genes, with 95% confidence intervals, as calculated by logistic regression analysis that included a random effect to adjust for repeated measurements. Differently colored and/or patterned lines correspond to significantly different genes (Tukey adjustment)](CAM4-8-1013-g002){#cam41985-fig-0002}

3.4. MSS viral genome detection in EBV‐negative PTLD {#cam41985-sec-0013}
----------------------------------------------------

The distribution of the different viruses in the EBV‐negative PTLD tissues is shown in Figure [1](#cam41985-fig-0001){ref-type="fig"} and is further described in [Supplementary Results](#cam41985-sup-0001){ref-type="supplementary-material"}.

3.5. Comparison of EBV and anellovirus detection methods {#cam41985-sec-0014}
--------------------------------------------------------

We confirmed that our tissue MSS results for EBV and anellovirus by quantitative tissue PCR. TTV levels by PCR were significantly higher in samples that were positive for anellovirus by MSS, compared to those that were negative by MSS (*P* \< 0.001, data not shown). Copy loads for EBV and TTV by PCR showed a modest but significant association with each other (Pearson correlation coefficient rho = 0.36, *P* \< 0.001, data not shown).

3.6. Survival analysis (patient death) {#cam41985-sec-0015}
--------------------------------------

### 3.6.1. Contingency analyses {#cam41985-sec-0016}

We first analyzed for survival outcomes in relation to MSS or qPCR results by using contingency analyses (Table [S1](#cam41985-sup-0001){ref-type="supplementary-material"}). Patient death within 5 years of PTLD diagnosis was associated with anellovirus (30% dead if negative vs 57% dead if positive; *P* = 0.037) and gammapapillomavirus (38% dead if negative and 86% dead if positive; *P* = 0.036) positivity by MSS. Death was not associated with EBV positivity (any method--clinical tumor positivity, MSS or PCR positivity), WHO classification type or early vs late onset PTLD. The only clinical parameter to associate with higher patient death in contingency analyses was liver location of PTLD (*P* = 0.031). Anellovirus tissue MSS positivity did not associate with PTLD WHO type, any specific location of PTLD or age at transplant.

### 3.6.2. Tissue qPCR {#cam41985-sec-0017}

We also analyzed the relationship between patient presentation or survival and levels of EBV and TTV measured by qPCR. Neither EBV PCR copy number nor TTV PCR copy number was associated with PTLD WHO type (data not shown). EBV PCR copy load did not associate with patient death (Figure [3](#cam41985-fig-0003){ref-type="fig"}A). In contrast, TTV PCR loads were significantly higher in patients who died (*P* = 0.032; Figure [3](#cam41985-fig-0003){ref-type="fig"}B). The median TTV copy number was 122 in the overall cohort and was 931 in patients who died within 5 years of PTLD diagnosis (vs 21 in those still alive at 5 years). Patient death occurred in 72% of those with TTV tissue load above the median of 122, whereas patient death was only 43% for those with TTV loads below the median (*P* = 0.024).

![Results of EBV or TTV quantitative PCR vs patient survival after PTLD. (A) Box and whiskers plot of EBV tissue PCR (copies/μg human DNA), stratified by patient alive or dead at 5 years after PTLD diagnosis (*P* = NS). (B) Box and whisker plot of TTV tissue PCR (copies/μg human DNA), where higher TTV qPCR loads were present in patients dead at 5 years after PTLD diagnosis (*P* = 0.032). The *Y*‐axis is shown on log base 10 scale. Values below detection limit were assigned a value of 0.00001. Data points correspond to the SAMPLES (there can be \>1/subject), and are "jittered" so that samples with overlapping markers are separated from each other. Box‐plot characteristics: Line = Median, Top edge of box = 75th percentile (Q3), Bottom edge of box = 25th percentile (Q1), Upper and lower whiskers = 1.5 × IQR (Q3‐Q1)](CAM4-8-1013-g003){#cam41985-fig-0003}

### 3.6.3. Time to event analyses {#cam41985-sec-0018}

We then analyzed covariate associations to patient death within 5 years of PTLD diagnosis using time‐to‐event analyses (Table [3](#cam41985-tbl-0003){ref-type="table"}). Univariable Cox regression analyses revealed that, liver, CNS or bone marrow locations of PTLD were significantly associated with worse patient survival. MSS positivity for anelloviridae (HR 2.00, 95% CI 0.09, 4.70, *P* = 0.09) and gammapapillomavirus (HR 2.38, 95% CI 0.87, 5.62, *P* = 0.06) trended toward worse patient survival. In subset sensitivity analyses where T cell PTLD was excluded, anellovirus positivity by MSS was significantly associated with patient death within 5 years of PTLD diagnosis ([Supplementary Results](#cam41985-sup-0001){ref-type="supplementary-material"}).

###### 

Univariable Cox regression analysis of relationship of covariates with patient death within 5 years of PTLD diagnosis

  Variable                                                                                  Reference group                              Hazard Ratio (95% CI)    *P*‐value
  ----------------------------------------------------------------------------------------- -------------------------------------------- ------------------------ ------------
  Age at transplant (Years)                                                                 Each 1 year age increment                    1.01 (0.99, 1.03)        0.18
  Male                                                                                      Female                                       0.97 (0.45,2.17)         0.94
  Transplant type                                                                                                                                                 
  Heart                                                                                     Bone marrow                                  0.33 (0.04,6.86)         0.85
  Liver                                                                                     Bone marrow                                  0.78 (0.10,15.98)        
  Lung                                                                                      Bone marrow                                  0.55 (0.10,10.15)        
  Multi‐organ                                                                               Bone marrow                                  0.58 (0.05,12.71)        
  Kidney                                                                                    Bone marrow                                  0.40 (0.06,7.69)         
  Locations of PTLD                                                                                                                                               
  Lymph node                                                                                Non‐lymph node location                      0.45 (0.15,1.09)         0.10
  GI tract                                                                                  Non‐GI tract location                        0.87 (0.34,1.97)         0.74
  **Liver**                                                                                 **Non‐liver location**                       **4.15 (1.20,11.17)**    **0.005**
  **CNS**                                                                                   **Non‐CNS location**                         **6.74 (0.36,36.73)**    **0.037**
  **Bone Marrow**                                                                           **Non‐bone marrow location**                 **14.74 (2.99,61.04)**   **\<.001**
  Lung                                                                                      Non‐lung location                            0.43 (0.07,1.47)         0.24
  Time from transplant to PTLD                                                                                                                                    
  1 year or above                                                                           \<1 year                                     0.81 (0.37,1.90)         0.61
  PTLD type                                                                                                                                                       
  Polymorphic                                                                               Non‐polymorphic                              0.66 (0.24,1.54)         0.36
  DLBCL                                                                                     Non‐DLBCL                                    1.25 (0.58,2.76)         0.57
  Classic Hodgkin                                                                           Non‐Hodgkin                                  0.35 (0.02,1.64)         0.28
  **T cell**                                                                                **Non‐T cell**                               **3.58 (1.04,9.40)**     **0.013**
  Burkitt lymphoma/plasma cell                                                              Non‐Burkitt/Plasma                           0.74 (0.04,3.48)         0.76
  Induction immunosuppression Regimen[\^](#cam41985-note-0011){ref-type="fn"} other         Anti‐thymocyte globulin                      0.87 (0.29,2.87)         0.22
  Unknown                                                                                   Anti‐thymocyte globulin                      0.55 (0.15,1.97)         
  Anti‐IL2 receptor                                                                         Anti‐thymocyte globulin                      1.74 (0.56,5.89)         
  **Log TTV copies/μg of Human DNA** [\*](#cam41985-note-0011){ref-type="fn"}               **Each 1 log increase**                      **1.10 (1.02,1.20)**     **0.016**
  **TTV‐ copies/μg of Human DNA: \>median** [\*](#cam41985-note-0011){ref-type="fn"}        **TTV‐1 copies/μg of Human DNA: ≤ median**   **2.23 (0.98,5.51)**     **0.058**
  Tumor EBV status (clinical testing) Any Positive[@](#cam41985-note-0011){ref-type="fn"}   Negative                                     0.55 (0.25,1.27)         0.14
  Log EBV copies/μg of Human DNA[\*](#cam41985-note-0011){ref-type="fn"}                    Each 1 log increase                          1.01 (0.93, 1.11)        0.76
  EBV copies/μg of Human DNA: \> median[\*](#cam41985-note-0011){ref-type="fn"}             EBV copies/μg of Human DNA: ≤ median         1.28 (0.57,2.97)         0.55
  MSS positive                                                                                                                                                    
  EBV                                                                                       Negative                                     0.67 (0.31,1.47)         0.30
  Cytomegalovirus                                                                           Negative                                     0.52 (0.03,2.47)         0.51
  HHV6 or 7                                                                                 Negative                                     1.15 (0.52,2.49)         0.73
  Simplexvirus                                                                              Negative                                     2.45 (0.14,11.84)        0.37
  BK_polyomavirus                                                                           Negative                                     4.76 (0.26,24.46)        0.10
  Merkel_cell_polyoma                                                                       Negative                                     0.52 (0.03,2.48)         0.52
  Alphapapillomavirus                                                                       Negative                                     1.05 (0.06,4.94)         0.97
  Betapapillomavirus                                                                        Negative                                     1.75 (0.68,4.00)         0.20
  **Gammapapillomavirus**                                                                   **Negative**                                 **2.38 (0.87,5.62)**     **0.06**
  Papillomaviridae                                                                          Negative                                     1.85 (0.44,5.32)         0.31
  Erythroparvovirus                                                                         Negative                                     0.76 (0.12,2.54)         0.70
  **Anelloviridae**                                                                         **Negative**                                 **2.00 (0.91,4.70)**     **0.09**

Number dead within 5 years = 26 and number alive at 5 years post‐PTLD = 34, except where marked separately.

^\^^Number dead = 25, number alive = 34, \*Number dead = 24, number alive = 33, ^@^Number dead = 25, number alive = 30.

For log‐transformed PCR values, 1 was added to all values to account for PCR copy number = 0, as log 0 is not defined and log 1 = 0.

PTLD locations were not mutually exclusive.

John Wiley & Sons, Ltd

A quantified TTV PCR load greater than the median of 122 copies/μg human DNA also trended with higher patient death (HR 2.23, 95% CI 0.98, 5.51, *P* = 0.058). Notably, the log‐transformed TTV viral load was strongly associated with patient death (hazard ratio 1.10, 95% confidence intervals 1.02, 1.20, *P* = 0.016), suggesting that higher tissue anellovirus quantity has a dose‐response relationship with patient death.

In contrast, EBV positivity by any method, including log‐transformed copy number, did not associate with patient death in time‐to‐event (Table [3](#cam41985-tbl-0003){ref-type="table"}) or sensitivity analyses ([Supplementary Results](#cam41985-sup-0001){ref-type="supplementary-material"}).

### 3.6.4. Multivariable analyses {#cam41985-sec-0019}

Finally, based on our univariate associations and known literature, we fitted a multivariate Cox regression model where 4 variables were considered for inclusion: age at transplant, T cell PTLD, log‐transformed EBV PCR copy number, log‐transformed TTV PCR copy number. Only T cell type PTLD (adjusted hazard ratio 4.14; 95% confidence intervals 1.18, 11.28, *P* = 0.006) and log‐transformed TTV PCR copy number (adjusted hazard ratio 1.11; 95% confidence intervals 1.02, 1.20, *P* = 0.012) remained independently significant.

4. DISCUSSION {#cam41985-sec-0020}
=============

In this study, we were able to successfully recover multiple DNA viral genomes from stored FFPE tissue, identify viruses in sequence data, and assess for sequence variants in key EBV genes. A key strength of our study was the broad range of viruses detectable, made possible by using a sequencing approach rather than a targeted PCR‐based approach. We are able to achieve a high degree of coverage of the EBV genome and detected many variants, across all the nine EBV genes tested. Certain EBV genes had higher percentages or proportions of nonsynonymous nucleotide variants.

Data on the genomic diversity of EBV and their contribution to PTLD pathogenesis or outcomes are scant, with small sample sizes in all, given the rarity of this disease. Vaysberg et al, from a panel of five EBV+ B cell lymphomas, identified three distinct and different variants of *LMP1*, with 2 gain of function mutations, which induced sustained MAP kinase activation and c‐Fos induction.[28](#cam41985-bib-0028){ref-type="ref"} Notably, we detected one of these gain of function mutations, S366T, in three of our polymorphic PTLD samples. Using FFPE tissues, Nourse et al found that EBV‐miRNA was profiled reliably within archival FFPE tissue in 14/23 patients, but not in tissues with low abundance of EBV.[29](#cam41985-bib-0029){ref-type="ref"} In subsequent studies, the same group found that nine CNS and 16 systemic PTLD tissues expressed similar viral latent (*EBNA2, EBNA3A, LMP1*) and lytic (*BZLF1, BRLF1, BLLF1*) gene mRNA transcripts.[30](#cam41985-bib-0030){ref-type="ref"}

From studies of other EBV‐associated cancers in a nontransplant setting in a general population, the genes *BRLF1*,*BBRF3*, and *BBLF2/BBLF3* had significant associations with gastric carcinoma.[31](#cam41985-bib-0031){ref-type="ref"} In Argentina, investigators detected an association between specific *BZLF1* gene variants such as *BZLF1‐A2* with lymphomas and *BZLF1‐C* with infectious mononucleosis.[32](#cam41985-bib-0032){ref-type="ref"} Specific polymorphisms in two viral gene promoters Cp and Qp were found in nasopharyngeal carcinoma.[33](#cam41985-bib-0033){ref-type="ref"} A clonal *LMP1* gene containing a 30 bp deletion (del30) was found in 46.1% of NK/T cell lymphomas and only in 4.8% of the controls, with much worse patient survival in those with this deletion.[34](#cam41985-bib-0034){ref-type="ref"} However, as shown in endemic Burkitt lymphoma, within a geographic region, different EBV genetic variations can coexist,[35](#cam41985-bib-0035){ref-type="ref"} such that specific gene variation associations with presentation or prognosis have been difficult. Although our study was not powered to detect individual variants associated with survival or PTLD type, we have demonstrated the technology can be successfully be used for this approach. The significance of specific EBV variants should be explored in future multicenter studies.

Prior studies of EBV‐negative DLBCL PTLD cases (n = 9) have shown that *human* gene alterations in these cases are more similar to those seen in immunocompetent Hodgkin lymphoma or non‐Hodgkin lymphoma, rather than the human gene alterations seen in EBV‐positive PTLDs (n = 24).[36](#cam41985-bib-0036){ref-type="ref"}, [37](#cam41985-bib-0037){ref-type="ref"} These results suggested that viral oncogenesis is not a key pathological pathway in EBV‐negative DLBCL PTLD. Our results, where no DNA viral genus was overrepresented in EBV‐negative PTLD tissue samples, would support this hypothesis, though our larger sample size of 27 EBV‐negative PTLDs is also relatively small.

While we are not aware of any reported association between gammapapillomavirus and degree of overall immunosuppression, the association of anellovirus positivity with patient death in our exploratory analyses was of particular interest. The biological significance of the entire anellovirus group is unknown and evolving.[38](#cam41985-bib-0038){ref-type="ref"}, [39](#cam41985-bib-0039){ref-type="ref"} Using cell‐free DNA sequencing from plasma samples derived from thoracic organ transplant recipients, De Vlaminck et al[40](#cam41985-bib-0040){ref-type="ref"} found a marked expansion of the annelloviridae family upon the onset of immunosuppression and a lower AnV burden with acute rejection episodes, even with appropriate drug immunosuppression levels. Blatter et al found that low AnV loads in pediatric lung transplant recipients at 2 weeks posttransplantation were more likely to develop acute rejection within 3 months after transplant (*P* = 0.013).[41](#cam41985-bib-0041){ref-type="ref"} High Anv loads from broncholaveolar lavage samples in lung transplant patients correlated with dysbiotic bacterial communities in the allograft. [42](#cam41985-bib-0042){ref-type="ref"} In adult kidney transplantation, low levels of AnV associated with higher risk of late acute antibody‐mediated rejection.[43](#cam41985-bib-0043){ref-type="ref"} These findings suggest that anelloviruses can be a biomarker for the overall degree of immunosuppression achieved.[40](#cam41985-bib-0040){ref-type="ref"}

Strengths of our study include demonstrating the feasibility of MSS of old, stored FFPE tissue for detection of *viral* genomes, the use of actual human PTLD specimens rather than in vitro cell lines to investigate for EBV variants, and the possible association with clinical presentations and outcomes. Limitations of the study include its single center and retrospective nature. Determining which microbial gene variants are pathogenic is more challenging than with human gene variants. In the latter, many resources are available to help determine pathogenicity, such as well‐annotated reference genomes, published literature on mutants that are associated with clinical pathology, and prediction models. Such tools are not as well‐developed for most microbial genome variants. An additional limitation of the MSS technology is its analysis of samples for short genomic reads, which may miss larger deletions. The fragmented nature of nucleic acid from FFPE tissue also compounds the difficulty in distinguishing true deletions from missing sequence coverage. For our MSS results, we emphasized specificity over sensitivity; our strictness in calling a sample positive may have been too stringent. EBV is the driver for PTLD onset,[2](#cam41985-bib-0002){ref-type="ref"}, [44](#cam41985-bib-0044){ref-type="ref"}, [45](#cam41985-bib-0045){ref-type="ref"}, [46](#cam41985-bib-0046){ref-type="ref"} thus other agents may act in the modulation of disease progression. Finally, patient survival can be very different in different organ transplants with different locations or WHO types of PTLD. We have accounted for WHO type; T cell PTLD remained independently significant in multivariate models, consistent with other recent reports.[47](#cam41985-bib-0047){ref-type="ref"} Certain individual locations were associated with higher risk of patient death in univariate analyses in our study, but each was present in very few subjects. Individual organ transplant type was not a significant univariate predictor in our study population. Notably, the prior PTLD‐1 trial evaluated survival after a common treatment regimen across different organ transplants and different WHO types. A completely homogenous PTLD study population is not possible given the relative rarity of this disease. Immunosuppression regimen associations were difficult to assess given the long time period when samples were acquired and the variety of regimens across organs.

In future, we expect to characterize further the specific types of EBV variants (single nucleotide variants, insertions, deletions, missense mutations, etc.) in the nine EBV genes we have analyzed so far. We will also expand our analyses to other EBV genes, using a larger cohort for greater power. Future studies could also involve laser capture of single malignant PTLD cells from tissue, and single cell RNA sequencing, but our study is the necessary first step.
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